Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
Senseonics tips 365-day CGM to double 2025 sales
Dive Brief: Senseonics expects the launch of its 365-day continuous glucose monitor (CGM) implant to help double its user base and sales in 2025, the